CTRP3 and Progranulin in Patients With Coronary Artery Disease

Implications of C1q/TNF-related Protein-3(CTRP-3) and Progranulin in Patients With Acutecoronary Syndrome and Stable Angina Pectoris

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01869816

Enrollment

362

Registered

2013-06-05

Start date

2011-03-01

Completion date

2012-12-31

Last updated

2020-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

CTRP-3, progranulin, coronary artery disease

Brief summary

Visceral obesity is the one of the major causes of cardiovascular morbidity and mortality in industrialized countries. Adipose tissue secretes various kinds of bioactive molecules termed adipokines which contribute to the development of obesity-related disorders including cardiovascular disease (CVD). Progranulin and CTRP3 are recently discovered novel adipokines. Therefore, the investigators tried to compare circulating CTRP-3 and progranulin levels in patients with CAD and investigated whether CTRP-3 or progranulin is significantly associated with CAD prevalence after adjustment for well-known CAD risk factors.

Detailed description

CTRP-3 (synonyms CORS-26, cartducin and cartonectin) is a potent anti-inflammatory adipokine that inhibits proinflammatory pathways in monocytes and adipocytes. Using a recently developed enzymelinked immunosorbent assay (ELISA), we reported that circulating CTRP-3 levels were elevated in patients with glucose metabolism dysregulation. Progranulin was identified as a key adipokine mediating high fat diet-induced insulin resistance and obesity through interleukin-6 (IL-6) in adipose tissue. We previously reported that progranulin levels were significantly higher in individuals with type 2 diabetes and were associated with macrophage infiltration in omental adipose tissue. Moreover, the expression of progranulin reduces inflammation and its degradation into granulins peptides enhances inflammation in atherosclerotic plaque, which may contribute to the progression of atherosclerosis There has been no previous report on the implication of CTRP-3 or progranulin in humans with cardiovascular disease (CAD). In the present study, we compared circulating CTRP-3 and progranulin levels in patients with CAD and investigated whether CTRP-3 or progranulin is significantly associated with CAD prevalence after adjustment for well known CAD risk factors.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* acute myocardial infarction * unstable angina * stable angina pectoris

Exclusion criteria

For control group, we exclude the participants who had * a history of CVD (myocardial infarction, unstable angina, stroke, or cardiovascular revascularization) * type 2 diabetes * stage 2 hypertension (resting blood pressure, ≥160/100 mmHg) * malignancy * severe renal or hepatic disease

Design outcomes

Primary

Measure	Time frame	Description
CTRP3	16 months	CTRP3 (ng/ml)

Secondary

Measure	Time frame	Description
SBP	16 months	SBP (mmHg)
LDL cholesterol	16 months	LDL (mg/dl)
hsCRP	16 months	hsCRP (mg/dl)
creatinine	16 months	creatinine (mg/dl)

Countries

South Korea

Outcome results